

1. Pezzino V, Vigneri R, Siperstein MD, Goldfine ID. Insulin and glucagon receptors in Morris hepatomas of varying growth rates. *Cancer Res* 39:1443-1446, 1979.
2. Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, Frittitta L, Vannelli GB, Brand R, Goldfine ID, Vigneri R. Elevated insulin receptor content in human breast cancer. *J Clin Invest* 86:1503-1510, 1990.
3. Papa V, Reese CC, Brunetti A, Vigneri R, Siiteri PK, Goldfine ID. Progestins increase insulin receptor content and insulin stimulation of growth in human breast carcinoma cells. *Cancer Res*; 50: 7858-7862, 1990.
4. Beck EP, Russo P, Gliozzo B, Jaeger W, Papa V, Wildt L, Pezzino V, Lang N. Identification of insulin and insulin-like growth factor I (IGF I) receptors in ovarian cancer tissue. *Gynecol Oncol* 53:196-201, 1994.
5. Muggeo M., Verlato G., Bonora E., Bressan G., Girotto S., Corbellini M., Gemma M.L., Moghetti P., Zenere M., Cacciatori V., Zoppini G., De Marco R. Verona Diabetes Study. A population-based survey on known diabetes mellitus prevalence and 5-yr all-cause mortality. *Diabetologia* 38: 318-325, 1995.
6. Muggeo M., Verlato G., Bonora E., Ciani F., Moghetti P., Eastman R., Crepaldi G., De Marco R.: Long-term instability of fasting plasma glucose predicts mortality in elderly type 2 diabetic patients. The Verona Diabetes Study. *Diabetologia* 38: 672-679, 1995.
7. Frittitta L., Vigneri R., Stampfer M.R., Goldfine I.D. Insulin receptor overexpression in 184B5 human mammary epithelial cells induces a liganddependent transformed phenotype. *J. Cell. Biochem*, 57: 666-669, 1995.
8. Costantino A., Vinci C., Mineo R, Frasca F., Pandini G., Milazzo G, Vigneri R., Belfiore A.: Interleukin-1 blocks insulin and insulin-like growth factor-stimulated growth in MCF-7 human breast cancer cells by inhibiting receptor tyrosine kinase activity. *Endocrinology* 137:4100-4107, 1996.
9. Belfiore A, Frittitta L, Costantino A, Frasca F, Pandini G, Sciacca L, Goldfine ID, Vigneri R. Insulin receptors in breast cancer. *Ann. NY. Acad. Sci.* 784:173-188, 1996.
10. Milazzo G, Sciacca L, Papa V, Goldfine ID, Vigneri R. ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: Evidence for enhanced interactions with the insulin-like growth factor-I receptor. *Mol. Carcinog.*, 18:19-25, 1997.
11. Muggeo M., Verlato G., Bonora E., Zoppini G., Corbellini M., De Marco R. Long-term instability of fasting plasma glucose: a novel predictor of cardiovascular mortality in elderly

- patients with non-insulin-dependent diabetes mellitus. The Verona Diabetes Study. *Circulation* 96: 1750-1754, 1997.
12. Frittitta L., Cerrato A., Sacco M.G., Weidner N., Goldfine I.D., Vigneri R.. The insulin receptor content is increased in breast cancers initiated by three different oncogenes in transgenic mice. *Br. Ca.. Res. Treat* 45: 141-147, 1997.
 13. Mathieu M.C., G.M.Clark , D.G.Allred , I.D. Goldfine, R.Vigneri Insulin receptor expression and clinical outcome in node-negative breast cancer. *Proc. Ass. Am. Physicians* 109: 465-571, 1997.
 14. De Marco R., Locatelli F., Zoppini G., Verlato G., Bonora E., Muggeo M. Cause-specific mortality in type 2 diabetes mellitus. The Verona Diabetes Study. *Diabetes Care* 22: 756-761, 1999.
 15. Bruno G, Merletti F, Boffetta P, Cavallo-Perin P, Barger G, Gallone G, Pagano G. Impact of glycemic control, hypertension and insulin-treatment on general and cause-specific mortality. An Italian population-based cohort of type 2 diabetes. *Diabetologia*;42:297-301, 1999.
 16. Zoppini G., Verlato G., Bonora E., Muggeo M. Attending the Diabetes Center is associated with reduced cardiovascular mortality in type 2 diabetic patients. The Verona Diabetes Study. *Diabetes Metab. Res. Rev.* 15: 170-174, 1999.
 17. Muggeo M., Bonora E. Predicting cardiovascular mortality in elderly diabetics. *Cardiol. Rev.* 16: 34-37, 1999.
 18. Traverso N, Menini S, Odetti P, Pronzato MA, Marinari UM. Lipoperoxidation in hepatic subcellular compartments of diabetic rats. *Free Radic Biol Med.* 26:538-47,1999.
 19. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, Vigneri R. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. *Mol. Cell. Biol.*, 19:3278-3288, 1999.
 20. Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, Scalia P, Sbraccia P, Goldfine ID, Vigneri R, Belfiore A. Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. *Oncogene.* 18:2471-2479, 1999.
 21. Marfella R, Giugliano D. Stress hyperglycaemia and death after myocardial infarction. *Lancet.* 355(9215):1647, 2000.
 22. Traverso N, Menini S, Odetti P, Pronzato MA, Cottalasso D, Marinari UM. Diabetes impairs the enzymatic disposal of 4-hydroxynonenal in rat liver. *Free Radic Biol Med.* 32:350-9, 2002.

23. Ottaviani F, Dozio N, Neglia C, Riccio S, Scavini M. Absence of otoacoustic emissions in insulin-dependent diabetic patients. Is there evidence for diabetic cochleopathy? *J Diabetes Complications* 16:338, 2002.
24. Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V, Belfiore A. A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. *J Clin Endocrinol Metab.* 87:245-254, 2002.
25. Sciacca L, Mineo R, Pandini G, Murabito A, Vigneri R, Belfiore A. In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. *Oncogene.* 21:8240-8250, 2002.
26. Sinagra D, Amato C, Scarpilta AM, Brigandì M, Amato M, Saura G, Latteri MA, Caimi G. Metabolic syndrome and breast cancer risk. *Eur Rev Med Pharmacol Sci.* 6(2-3):55-9, 2002.
27. Sciacca L, Prisco M, Wu A, Belfiore A, Vigneri R, Baserga R. Signaling differences from the A and B isoforms of the insulin receptor in 32D cells in the presence or absence of IRS-1. *Endocrinology.* 144:2650-2658, 2003.
28. Verlato G., Zoppini G., Bonora E., Muggeo M. Mortality from site-specific malignancies in type 2 diabetic patients from Verona. *Diabetes Care* 26: 1047-1051, 2003.
29. Zoppini G., Verlato G., Leuzinger C., Zamboni C., Brun E., Bonora E., Muggeo M. Body mass index and the risk of mortality in type 2 diabetic patients from Verona. *Int. J. Obes.* 27: 281-185, 2003.
30. Bruno G, Merletti F, Biggeri A, Bargerò G, Ferrero S, Runzo C, Prina Cerai S, Pagano G, Cavallo Perin P. Metabolic syndrome as predictor of all-causes and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. *Diabetes Care.* 27:2689-94, 2004.
31. Paonessa F, Foti D, Costa V, Chiefari E, Brunetti G, Leone F, Luciano F, Wu F, Lee AS, Gulletta E, Fusco A, Brunetti A. Activator protein-2 overexpression accounts for increased insulin receptor expression in human breast cancer. *Cancer Res* 66: 5085-5093, 2006.
32. Salonia A, Lanzi R, Scavini M, Pontillo M, Gatti E, Petrella G, Licata G, Nappi RE, Bosi E, Briganti A, Rigatti P, Montorsi F. Sexual function and endocrine profile in fertile women with type 1 diabetes mellitus. *Diabetes Care* 29:312-316, 2006.
33. Zoppini G, Verlato G, Zamboni C, Venturi C, Gennaro N, Biasi V, Bonora E, Muggeo M. Pulse pressure and mortality from cerebrovascular diseases in Type 2 diabetic patients: The Verona Diabetes Study. *Cerebrovasc. Dis.* 23: 20-26, 2007.
34. Frasca F, Pandini G, Malaguarnera R, Mandarino A, Messina RL, Sciacca L, Belfiore A, Vigneri R. Role of c-Abl in Directing Metabolic versus Mitogenic Effects in Insulin Receptor Signaling. *J. Biol. Chem.* 282:26077-26088, 2007.

35. Zoppini G., Verlato G., Targher G., Bonora E., Trombetta M., Muggeo M. Variability of body weight, pulse pressure and glycaemia strongly predict total mortality in elderly type 2 diabetic patients. The Verona Diabetes Study. *Diabetes Metab. Res. Rev.* 24: 624-628, 2008.
36. Costa V, Foti D, Paonessa F, Chiefari E, Palaia L, Brunetti G, Gulletta E, Fusco A, Brunetti A. The insulin receptor: a new anticancer target for peroxisome proliferator-activated receptor-gamma (PPARgamma) and thiazolidinedione-PPARgamma agonists. *Endocr Relat Cancer*; 15: 325-35, 2008.
37. Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, Vigneri R. The role of insulin receptors and IGF-I receptors in cancer and other diseases. *Arch Physiol Biochem.* 114:23-37, 2008.
38. Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH; EURODIAB Prospective Complications Study Group. Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). *Diabetes Care.* 31:1360-1366, 2008.
39. Zoppini G., Targher G., Negri C., Stoico V., Perrone F., Muggeo M., Bonora E. Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients. *Diabetes Care* 32: 1716-1720, 2009.
40. Genua M., Pandin iG., Sisci D., Castoria G., Maggiolini M., Vigneri R., Belfiore A. Role of Cyclic AMP Response Element-Binding Protein in Insulin-like Growth Factor-I Receptor Up-regulation by Sex Steroids in Prostate Cancer Cells. *Cancer Res*: 69: 7270-7277, 2009.
41. Bruno G, Cerutti F, Merletti F, Novelli G, Panero F, Zucco C, Cavallo-Perin P, Piedmont Study Group for Diabetes Epidemiology. Short-term mortality risk in children and young adults with type 1 diabetes: the population-based Registry of the Province of Torino, Italy. *Nutr Metab Cardiovasc Dis.* 19:340-44, 2009.
42. Foti DP, Paonessa F, Chiefari E, Brunetti A. New target genes for the peroxisome proliferator-activated receptor- γ (PPAR γ) antitumour activity: Perspectives from the insulin receptor. *PPAR Res*; 2009: 571365, 2009.
43. Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, Longhi A, Zakikhani M, Carboni JM, Gottardis M, Giunti A, Pollak M, Vigneri R, Baldini N. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. *Cancer Res.* 69:2443-2452, 2009.
44. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and Cancer. *Endocr Relat Cancer* 16:1103-1123, 2009.

45. Vigneri R, Frasca F, Sciacca L, Vigneri P, Frittitta L. Re: Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. *J Natl Cancer Inst.*, 101:1030-1031, 2009.
46. Vigneri R. Diabetes therapy and cancer risk. *Nature Rev/Endocrinology*: 5: 651-652, 2009
47. Aiello A., Pandini G., Sarfstein R., Werner H., Manfioletti G., Vigneri R., Belfiore A. HMGA1 protein is a positive regulator of the insulin-like growth factor-I receptor gene. *Eur. J. Cancer*: 46: 1919-26, 2010.
48. Vigneri R, Sava L, Squatrito S, Sciacca L. Comment on: Yang et al. (2010) Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong Diabetes Registry. *Diabetes*; 59:1254-1260. *Diabetes*. 59:e24, 2010.
49. Zoppini G., Targher G., Chonchol M., Negri C., Stoico V., Pichiri I., Lippi G., Muggeo M., Bonora E. Anaemia, independent of chronic kidney disease, predicts all-cause and cardiovascular mortality in type 2 diabetic patients. *Atherosclerosis* 210: 575-580, 2010.
50. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G, Pederzoli P, Croce CM, Scarpa A. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. *J Clin Oncol.* 28(2):245-55, 2010.
51. Marchesi F, Piemonti L, Mantovani A, Allavena P. Molecular mechanisms of perineural invasion, a forgotten pathway of dissemination and metastasis. *Cytokine Growth Factor Rev.* 21(1):77-82, 2010.
52. Zhou W, Capello M, Fredolini C, Piemonti L, Liotta LA, Novelli F, Petricoin EF. Mass Spectrometry Analysis of the Post-Translational Modifications of alpha-Enolase from Pancreatic Ductal Adenocarcinoma Cells. *J Proteome Res.* 9(6):2929-36, 2010.
53. Zhou W, Capello M, Fredolini C, Piemonti L, Liotta LA, Novelli F, Petricoin EF. Proteomic analysis of pancreatic ductal adenocarcinoma cells reveals metabolic alterations *J Proteome Res.* 10(4):1944-52, 2011.
54. Calori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, Villa M, Bosi E, Ruotolo G, Piemonti L, Perseghin G Fatty Liver Index (FLI) and mortality: the Cremona Study at the 15th year of follow up. *Hepatology.* 54(1):145-52, 2011.
55. Iacobini C, Menini S, Ricci C, Blasetti Fantauzzi C, Scipioni A, Salvi L, Cordone S, Delucchi F, Serino M, Federici M, Pricci F, Pugliese G. Galectin-3 ablation protects mice from diet-induced nonalcoholic steatohepatitis. Major scavenging role of galectin-3 in liver. *J Hepatol.* 54:975-983, 2011.

56. Arcidiacono B, Iiritano S, Nocera A, Possidente K, Nevolo MT, Ventura V, Foti D, Chiefari E, Brunetti A. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. *Exp Diabetes Res* 2012: 789174, 2012.
57. Zhou W, Capello M, Fredolini C, Racanicchi L, Piemonti L, Liotta LA, Novelli F, Petricoin EF Proteomic Analysis Reveals Warburg Effect and Anomalous Metabolism of Glutamine in Pancreatic Cancer Cells. *J Proteome Res.* 3;11(2):554-63, 2012.
58. Malaguarnera R., Sacco A., Voci C., Pandini G., Vigneri R., Belfiore A. Proinsulin Binds with High Affinity the Insulin receptor Isoform A and Predominantly Activates the Mitogenic Pathway *Endocrinology*: 153(5): 2152-2163, 2012.
59. Vigneri R., Vigneri P., Frittitta L. Basal Insulin and cardiovascular and other outcomes. *N. Eng. J. Med.*: 367; 18: 1761-1762, 2012.
60. Corno D, Pala M, Cominelli M, Cipelletti B, Leto K, Croci L, Barili V, Brandalise F, Melzi R, Di Gregorio A, Sergi L, SL Politi, Piemonti L, Bulfone A, Rossi P, Rossi F, Consalez GG, Poliani PL, Galli R. Gene signatures associated with mouse postnatal hindbrain neural stem cells and medulloblastoma cancer stem cells identify novel molecular mediators and predict human MB molecular classification. *Cancer Discov.* 2(6):554-68, 2012.
61. Zhou W, Capello M, Fredolini C, Racanicchi L, Piemonti L, Liotta LA, Novelli F, Petricoin EF Mass spectrometry analysis reveals O-methylation of L-lactate dehydrogenase from pancreatic ductal adenocarcinoma cells. *Electrophoresis.* 33(12):1850-4, 2012.
62. Avnet S, Perut F, Salerno M, Sciacca L, Baldini N. Insulin receptor isoforms are differently expressed during human osteoblastogenesis. *Differentiation* 83:242–248, 2012.
63. Dynkevich Y., Rother K.I. Whitford I., Qureshi S., Galiveeti S., Szulc A.L., Danoff A., Breen T.L., Kaviani N., Shanik M.H., LeRoith D., Vigneri R., Koch C.A. Roth J. Tumors, IGF-2 and Hypoglycemia: Insight from the clinic, the laboratory and the historical archive. *Endocrine Reviews.* 34 (6): 798-826, 2013.
64. Sciacca L, Vigneri R, Tumminia A, Frasca F, Squatrito S, Frittitta L, Vigneri P. Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. *Nutr Metab Cardiovasc Dis.* 23:808-815, 2013.
65. Giovinazzo F, Malpeli G, Zanini S, Parenti M, Piemonti L, Colombatti M, Valenti MT, Carbonare LD, Scarpa A, Sinnott-Smith J, Rozengurt E, Bassi C, Innamorati G. Ectopic expression of the heterotrimeric G15 protein in pancreatic carcinoma and its potential in cancer signal transduction. *Cell Signal.* 25(3):651-9, 2013.
66. Marquard J, Welters A, Buschmann T, Barthlen W, Vogelgesang S, Klee D, Krausch M, Raffel A, Otter S, Piemonti L, Mayatepek E, Otonkoski T, Lammert E, Meissner T.

- Association of exercise-induced hyperinsulinaemic hypoglycaemia with MCT1-expressing insulinoma. *Diabetologia*. 56(1):31-5, 2013.
67. Zhou W, Capello M, Fredolini C, Racanicchi L, Dugnani E, Piemonti L, Liotta LA, Novelli F, Petricoin EF. Mass spectrometric analysis reveals O-methylation of pyruvate kinase from pancreatic cancer cells. *Anal Bioanal Chem*. 405(14):4937-43, 2013.
68. Perotto M, Panero F, Gruden G, Fornengo P, Lorenzati B, Barutta F, Ghezzo G, Amione C, Cavallo Perin P, Bruno G. Obesity and mortality in type 2 diabetes: the Casale Monferrato Study. *Acta Diabetologica*. 50:563-68, 2013.
69. De Cosmo S, Copetti M, Lamacchia O, Fontana A, Massa M, Morini E, Pacilli A, Fariello S, Palena A, Rauseo A, Viti R, Di Paola R, Menzaghi C, Cignarelli M, Pellegrini F, Trischitta V. Development and validation of a predicting model of all-cause mortality in patients with type 2 diabetes. *Diabetes Care* 36(9):2830-5, 2013
70. . Napoli N., Strollo R, Pitocco D., Bizzarri C., Maddaloni E, Maggi D., Manfrini S., Schwartz A., Pozzilli P, Effect of calcitriol on bone turnover and osteocalcin in recent-onset type 1 diabetes. *PloS One*, 8(2) e56488,2013.
71. Conti F, Wolosinska DT, Pugliese G. Diabetes and bone fragility: a dangerous liaison. *Aging Clin Exp Res*. 25:S39-S41, 2013.
72. Maddaloni E., D'Onofrio L., Lauria A., Maurizi AR., Strollo R, Palermo A., Napoli N., Angeletti S., Pozzilli P, Manfrini S. Osteocalcin levels are inversely associated with HbA1c and BMI in adult subjects with long-standing type 1 diabetes. *J Endocrinol Invest*, vol. 37, no. 7, pp 661-666, 2014.
73. Sciacca L, Cassarino MF, Genua M, Vigneri P, Pennisi MG, Malandrino P, Squatrito S, Pezzino V, Vigneri R. Biological effects of insulin and its analogs on cancer cells with different insulin family receptor expression. *J Cell Physiol*. 229:1817-1821, 2014.
74. Balzano G, Dugnani E, Pasquale V, Capretti G, Radaelli MG, Garito T, Stratta G, Nini A, Di Fenza R, Castoldi R, Staudacher C, Reni M, Scavini M, Doglioni C, Piemonti L. Clinical signature and pathogenetic factors of diabetes associated with pancreas disease (T3cDM): a prospective observational study in surgical patients. *Acta Diabetol*. 51(5):801-11, 2014.
75. Zoppini G., Fedeli U., Gennaro N., Saugo M., Targher G., Bonora E. Mortality from chronic liver diseases in diabetes. *Am J Gastroenterol*. 109: 1020-1025, 2014.
76. Balducci S, Sacchetti M, Orlando G, Salvi L, Pugliese L, Salerno G, D'Errico V, Iacobini C, Conti FG, Zanuso S, Nicolucci A, Pugliese G, for the Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes (SAMBA) Investigators. Correlates of muscle strength in diabetes. The Study on the Assessment of

- Determinants of Muscle and Bone Strength Abnormalities in Diabetes (SAMBA). *Nutr Metab Cardiovasc Dis.* 24:18, 2014.
77. Mameli C, Mazzantini S, Ben Nasr M, Fiorina P, Scaramuzza AE, Zuccotti GV. Explaining the increased mortality in type 1 diabetes. *World J Diabetes.* 6(7):889-95, 2015.
78. Zhukouskaya VV, Eller Vainicher C, Gaudio A, Cairoli E, Massimo Ulivieri F, Palmieri S, Morelli V, Orsi E, Masserini B, Maria Barbieri A, Polledri E, Fustinoni S, Spada A, Erio Fiore C, Chiodini I. In postmenopausal female subjects with type 2 diabetes mellitus vertebral fractures are independently associated with cortisol secretion and sensitivity. *J Clin Endocrinol Metab.* 100:1417-25, 2015.
79. Ballotari P, Ranieri SC, Luberto F, Caroli S, Greci M, Giorgi Rossi P, Manicardi V. Sex differences in cardiovascular mortality in diabetics and nondiabetic subjects: a population-based study (Italy). *Int J Endocrinol.* 2015:91405, 2015.
80. Pacilli A, Lamacchia O, Fontana A, Copetti M, Cignarelli M, Trischitta V, De Cosmo S. Target values of cardiovascular risk factors are not associated with all-cause mortality in patients with type 2 diabetes mellitus. *PLoS One.* 10(4):e0124536, 2015.
81. Barchetta I, Capoccia D, Baroni MG, Buzzetti R, Cavallo MG, De Cosmo S, Leonetti F, Leotta S, Morano S, Morviducci L, Prudente S, Pugliese G, Trischitta V; SUMMER Study in Diabetes Group. The "Sapienza University Mortality and Morbidity Event Rate (SUMMER) study in diabetes": Study protocol. *Nutr Metab Cardiovasc Dis.* 26(2):103-8, 2016.
82. Zoppini G, Cacciatori V, Negri C, Stoico V, Lippi G, Targher G, Bonora E. The aspartate aminotransferase-to-alanine aminotransferase ratio predicts all-cause and cardiovascular mortality in patients with type 2 diabetes. *Medicine (Baltimore).* 95(43):e4821, 2016.
83. Ortega Moreno L, Lamacchia O, Salvemini L, De Bonis C, De Cosmo S, Cignarelli M, Trischitta V, Menzaghi C. The paradoxical association of adiponectin with mortality rate in patients with type 2 diabetes: evidence of synergism with kidney function. *Atherosclerosis.* 245:222-7, 2016.
84. Pontiroli AE, Zakaria AS, Mantegazza E, Morabito A, Saibene A, Mozzi E, Micheletto G; LAGB10 working group. Long-term mortality and incidence of cardiovascular diseases and type 2 diabetes in diabetic and nondiabetic obese patients undergoing gastric banding: a controlled study. *Cardiovasc Diabetol.* 15:39, 2016.
85. Bo S, Ponzio V, Goitre I, Fadda M, Pezzana A, Beccuti G, Gambino R, Cassader M, Soldati L, Broglio F. Predictive role of the Mediterranean diet on mortality in individuals at low

cardiovascular risk: a 12-year follow-up population-based cohort study. *J Transl Med.* 14:91, 2016.

86. Targher G, Dauriz M, Laroche C, Temporelli PL, Hassanein M, Seferovic PM, Drozd J, Ferrari R, Anker S, Coats A, Filippatos G, Crespo-Leiro MG, Mebazaa A, Piepoli MF, Maggioni AP, Tavazzi L; ESC-HFA HF Long-Term Registry investigators. In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. *Eur J Heart Fail.* 19:54-65, 2017.
87. Rossi A, Zoppini G, Benfari G, Geremia G, Bonapace S, Bonora E, Vassanelli C, Enriquez-Sarano M, Targher G. Mitral Regurgitation and Increased Risk of All-Cause and Cardiovascular Mortality in Patients with Type 2 Diabetes. *Am J Med.* 130(1):70-76.e1, 2017.
88. Mantovani A, Perrone F, Stoico V, Pichiri I, Salvotelli L, Teobaldi I, Bruti M, Conti M, Cima L, Eccher A, Bonora E. Primary cutaneous B-cell lymphoma and chronic leg ulcers in a patient with type 2 diabetes. *Endocrinol Diabetes Metab Case Rep.* 2017 May 24;2017.
89. Dauriz M, Targher G, Temporelli PL, Lucci D, Gonzini L, Nicolosi GL, Marchioli R, Tognoni G, Latini R, Cosmi F, Tavazzi L, Maggioni AP; GISSI-HF Investigators. Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial. *J Am Heart Assoc.* 6(7), 2017.
90. Targher G, Dauriz M, Laroche C, Temporelli PL, Hassanein M, Seferovic PM, Drozd J, Ferrari R, Anker S, Coats A, Filippatos G, Crespo-Leiro MG, Mebazaa A, Piepoli MF, Maggioni AP, Tavazzi L; ESC-HFA HF Long-Term Registry investigators. In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. *Eur J Heart Fail.* 19(1):54-65, 2017.
91. Conti F, Balducci S, Pugliese L, D'Errico V, Vitale M, Alessi E, Salerno G, Iacobini C, Menini S, Bollanti L, Nicolucci A, Pugliese G. Correlates of Calcaneal Quantitative Ultrasound Parameters in Patients with Diabetes: The Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes. *J Diabetes Res.* 2017:4749619, 2017.
92. Lamacchia O, Fontana A, Pacilli A, Copetti M, Fariello S, Garofolo M, Penno G, Trischitta V, De Cosmo S, Cignarelli M. On the non-linear association between serum uric acid levels and all-cause mortality rate in patients with type 2 diabetes mellitus. *Atherosclerosis.* 260:20-26, 2017.

93. Fontana A, Ortega Moreno L, Lamacchia O, De Bonis C, Salvemini L, De Cosmo S, Cignarelli M, Copetti M, Trischitta V, Menzaghi C. Serum resistin is causally related to mortality risk in patients with type 2 diabetes: preliminary evidences from genetic data. *Sci Rep.* 7(1):61, 2017.
94. Maddaloni E, D'Eon S, Hastings S, Tinsley LJ, Napoli N, Khamaisi M, Bouxsein ML, Fouda SM, Keenan HA. Bone health in subjects with type 1 diabetes for more than 50 years. *Acta Diabetol.* 54(5):479-488, 2017.
95. Ballotari P, Vicentini M, Manicardi V, Gallo M, Chiatamone Ranieri S, Greci M, Giorgi Rossi P. Diabetes and risk of cancer incidence: results from a population-based cohort study in northern Italy. *BMC Cancer.* 17(1):703, 2017.
96. Orsi E, Solini A, Bonora E, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Gruden G, Morano S, Nicolucci A, Penno G, Pugliese G; Renal Insufficiency and Cardiovascular Events (RIACE) Study Group. Haemoglobin A1c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes. *Diabetes Obes Metab.* 20(8):1885-1893, 2018.
97. Bonora E, Monami M, Bruno G, Zoppini G, Mannucci E. Attending Diabetes Clinics is associated with a lower all-cause mortality. A meta-analysis of observational studies performed in Italy. *Nutr Metab Cardiovasc Dis.* 28(5):431-435, 2018.
98. Zoppini G, Fedeli U, Schievano E, Dauriz M, Targher G, Bonora E, Corti MC. Mortality from infectious diseases in diabetes. *Nutr Metab Cardiovasc Dis.* 28(5):444-450, 2018.
99. De Carli L, Gambino R, Lubrano C, Rosato R, Bongiovanni D, Lanfranco F, Broglio F, Ghigo E, Bo S. Impaired taste sensation in type 2 diabetic patients without chronic complications: a case-control study. *J Endocrinol Invest.* 41(7):765-772, 2018.
100. Napoli N, Strollo R, Defeudis G, Leto G, Moretti C, Zampetti S, D'Onofrio L, Campagna G, Palermo A, Greto V, Manfrini S, Hawa MI, Leslie RD, Pozzilli P, Buzzetti R; NIRAD (NIRAD 10) and Action LADA Study Groups. Serum Sclerostin and Bone Turnover in Latent Autoimmune Diabetes in Adults. *J Clin Endocrinol Metab.* 1;103(5):1921-1928, 2018.
101. Parodi A, Castello M, Corbetta S, Cordera R, Cristaudo A, Cucchia R, Guazzoni V, Leuzzi M, Mussini A, Patrizi A, Pigatto P, Regazzini R, Rizzo D, Stingeni L, Zichichi L. Skin and diabetes: an experts' opinion from the Italian diabetologists and dermatologists of the DiaDex group. *G Ital Dermatol Venereol.* 153(5):649-658, 2018.

102. Cignarelli A, Genchi VA, Caruso I, Natalicchio A, Perrini S, Laviola L, Giorgino F. Diabetes and cancer: Pathophysiological fundamentals of a 'dangerous affair'. *Diabetes Res Clin Pract.* 143:378-388, 2018.
103. Lisco G, Cicco G, Cignarelli A, Garruti G, Laviola L, Giorgino F. Computerized Video-Capillaroscopy Alteration Related to Diabetes Mellitus and Its Complications. *Adv Exp Med Biol.* 1072:363-368, 2018.
104. Vella V, Milluzzo A, Scalisi NM, Vigneri P, Sciacca L. Insulin Receptor Isoforms in Cancer. *Int J Mol Sci.* 19(11), 2018.
105. Sciacca L, Vella V, Frittitta L, Tumminia A, Manzella L, Squatrito S, Belfiore A, Vigneri R. Long-acting insulin analogs and cancer. *Nutr Metab Cardiovasc Dis.* 28(5):436-443, 2018.
106. Sassi F, Buondonno I, Luppi C, Spertino E, Stratta E, Di Stefano M, Ravazzoli M, Isaia G, Trento M, Passera P, Porta M, Isaia GC, D'Amelio P. Type 2 diabetes affects bone cells precursors and bone turnover. *BMC Endocr Disord.* 18(1):55, 2018.
107. Mantovani A, Sani E, Fassio A, Colecchia A, Viapiana O, Gatti D, Idolazzi L, Rossini M, Salvagno G, Lippi G, Zoppini G, Byrne CD, Bonora E, Targher G. Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes. *Diabetes Metab.* 45(4):347-55, 2019.
108. Pontiroli AE, Ceriani V, Sarro G, Micheletto G, Giovanelli A, Zakaria AS, Fanchini M, Osio C, Nosari I, Veronelli AM, Folli F; LAGB10 working group. Incidence of Diabetes Mellitus, Cardiovascular Diseases, and Cancer in Patients Undergoing Malabsorptive Surgery (Biliopancreatic Diversion and Biliointestinal Bypass) vs Medical Treatment. *Obes Surg.* 29(3):935-942, 2019.
109. Copetti M, Shah H, Fontana A, Scarale MG, Menzaghi C, De Cosmo S, Garofolo M, Sorrentino MR, Lamacchia O, Penno G, Doria A, Trischitta V. Estimation of Mortality Risk in Type 2 Diabetic Patients (ENFORCE): An Inexpensive and Parsimonious Prediction Model. *J. Clin. Endocrinol. Metab.* 104:4900-4908, 2019.
110. Ceriani V, Sarro G, Micheletto G, Giovanelli A, Zakaria AS, Fanchini M, Osio C, Nosari I, Morabito A, Pontiroli AE; LAGB10 working group. Long-term mortality in obese subjects undergoing malabsorptive surgery (biliopancreatic diversion and biliointestinal bypass) versus medical treatment. *Int J Obes (Lond).* 43(6):1147-1153, 2019
111. Geagea AG, Rizzo M, Jurjus A, Cappello F, Leone A, Tomasello G, Gracia C, Al Kattar S, Massaad-Massade L, Eid A. A novel therapeutic approach to colorectal cancer in diabetes: role of metformin and rapamycin. *Oncotarget.* 10:1284-1305, 2019.

112. Milluzzo A, Tumminia A, Vella V, Gianì F, Manzella L, Frittitta L, Belfiore A, Vigneri R, Sciacca L. Short-term adverse effects of anticancer drugs in patients with type 2 diabetes. *J. Chemother.* 31:150-159, 2019.
113. Garofolo M, Gualdani E, Giannarelli R, Aragona M, Campi F, Lucchesi D, Daniele G, Miccoli R, Francesconi P, Del Prato S, Penno G. Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study. *Cardiovasc Diabetol*, 18:159, 2019.
114. Lippi G, Targher G. Increased red blood cell distribution width and platelet-to-lymphocyte ratio for predicting all-cause mortality in patients with type 2 diabetes and advanced heart failure: a causal association or epiphenomenon? *Kardiol Pol.* 77(6):587-588, 2019.
115. De Rocco Ponce M, Garolla A, Caretta N, De Toni L, Avogaro A, Foresta C. Estradiol correlates with erectile dysfunction and its severity in type 2 diabetic patients. *J Diabetes Complications.* 34(12):107728, 2020.
116. Dei Cas A, Aldigeri R, Ridolfi V, Vazzana A, Ciardullo AV, Manicardi V, Sforza A, Tomasi F, Zavaroni D, Zavaroni I, Bonadonna RC. A performance score of the quality of inpatient diabetes care is a marker of clinical outcomes and suggests a cause-effect relationship between hypoglycaemia and the risk of in-hospital mortality. *Diabetes Metab Res Rev.* 36(8):e3347, 2020.
117. Pagano E, Konings SRA, Di Cuonzo D, Rosato R, Bruno G, van der Heijden AA, Beulens J, Slieker R, Leal J, Feenstra TL Prediction of mortality and major cardiovascular complications in type 2 diabetes: External validation of UK Prospective Diabetes Study outcomes model version 2 in two European observational cohorts. *Diabetes Obes Metab.* [Epub ahead of print], 2020.
118. Rizza S, Rossini V, Cardellini M, Luzi A, Longo S, Piciucchi G, Coppeta L, Federici M. Diabetes influences cancer risk in patients with increased carotid atherosclerosis burden. *Nutr Metab Cardiovasc Dis.* 30(4):652-655, 2020.
119. Valentini A, Cianfarani MA, Federici M, Tarantino U, Bertoli A. Osteoprotegerin in diabetic osteopathy. *Nutr Metab Cardiovasc Dis.* 30(1):49-55, 2020.
120. Fiorillo C, Quero G, Laterza V, Mascagni P, Longo F, Menghi R, Razionale F, Rosa F, Mezza T, Boskoski I, Giaccari A, Alfieri S. Postoperative hyperglycemia affects survival after gastrectomy for cancer: A single-center analysis using propensity score matching. *Surgery.* 167(5):815-820, 2020.

121. Caruso I, Giorgino F. The diabetic lung: An easy target for SARS-CoV-2? *Diabetes Metab Res Rev.* 36(8):e3346, 2020.
122. Scarale MG, Copetti M, Garofolo M, Fontana A, Salvemini L, De Cosmo S, Lamacchia O, Penno G, Trischitta V, Menzaghi C. The Synergic Association of hs-CRP and Serum Amyloid P Component in Predicting All-Cause Mortality in Patients With Type 2 Diabetes. *Diabetes Care.* 43(5):1025-1032, 2020.
123. Garofolo M, Gualdani E, Scarale MG, Bianchi C, Aragona M, Campi F, Lucchesi D, Daniele G, Miccoli R, Francesconi P, Del Prato S, Penno G. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study. *Diabetes Care.* 43(10):e139-e141, 2020.
124. Cannata F, Vadalà G, Ambrosio L, Napoli N, Papalia R, Denaro V, Pozzilli P. The impact of type 2 diabetes on the development of tendinopathy. *Diabetes Metab Res Rev.* [Epub ahead of print], 2020.
125. Piccoli A, Cannata F, Strollo R, Pedone C, Leanza G, Russo F, Greto V, Isgrò C, Quattrocchi CC, Massaroni C, Silvestri S, Vadalà G, Bisogno T, Denaro V, Pozzilli P, Tang SY, Silva MJ, Conte C, Papalia R, Maccarrone M, Napoli N. Sclerostin Regulation, Microarchitecture, and Advanced Glycation End-Products in the Bone of Elderly Women With Type 2 Diabetes. *J Bone Miner Res.* 35(12):2415-2422, 2020.
126. Cannata F, Vadalà G, Ambrosio L, Napoli N, Papalia R, Denaro V, Pozzilli P. Osteoarthritis and type 2 diabetes: From pathogenetic factors to therapeutic intervention. *Diabetes Metab Res Rev.* 36(3):e3254, 2020.
127. Vigneri R, Sciacca L, Vigneri P. Rethinking the Relationship between Insulin and Cancer. *Trends Endocrinol Metab.* 31(8):551-560, 2020.
128. Monami M, Candido R, Pintaudi B, Targher G, Mannucci E; SID-AMD joint Panel for Italian Guidelines on Treatment of Type 2 Diabetes. Effect of metformin on all-cause mortality and major adverse cardiovascular events: An updated meta-analysis of randomized controlled trials. *Nutr Metab Cardiovasc Dis.* S0939-4753(20)30508-1, 2020.
129. Tilg H, Targher G. NAFLD-related mortality: simple hepatic steatosis is not as 'benign' as thought. *Gut.* gutjnl-2020-323188, 2020.
130. Ghio S, Klersy C, Carluccio E, Scardovi AB, Scelsi L, Falletta C, Rossi A, Faggiano P, Traversi E, Vriz O, Guazzi M, Dini FL, Targher G, Temporelli PL. Pre-existing type 2 diabetes is associated with increased all-cause death independently of echocardiographic predictors of poor prognosis only in ischemic heart disease. *Nutr Metab Cardiovasc Dis.* 30(11):2036-2040, 2020.

- 131.** Mannucci E, Monami M, Candido R, Pintaudi B, Targher G; SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes. Effect of insulin secretagogues on major cardiovascular events and all-cause mortality: A meta-analysis of randomized controlled trials. *Nutr Metab Cardiovasc Dis.* 30(10):1601-1608, 2020.
- 132.** Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. *Metabolism.* 111S:154170, 2020.